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Superficial, Nodular, and Morpheiform Basal-Cell
Carcinomas Exhibit Distinct Gene Expression Profiles
Mei Yu1,2, David Zloty1, Bryce Cowan1, Jerry Shapiro1, Anne Haegert3, Robert H. Bell3, Larry Warshawski1,
Nicholas Carr4 and Kevin J. McElwee1,2
Basal-cell carcinoma (BCC), the most common neoplasm in humans, occurs in a variety of morphological
presentations. The mechanisms of BCC development downstream of the initial genetic mutations are not well
understood, and different BCC morphological presentations might exhibit distinct gene expression patterns.
We investigated superficial (n¼ 8), nodular (n¼ 8), and morpheiform (n¼ 7) BCCs using 21K cDNA microarrays.
Global gene expression profiles between respective BCC subtypes, and as compared with normal skin (n¼ 8),
were statistically defined by significance analysis of microarrays (SAM). Thirty-seven genes were subsequently
validated by quantitative reverse transcriptase-PCR analysis using an expanded set of 31 BCCs. Gene ontology
analysis indicated that gene expression patterns of BCC subtypes in multiple biological processes showed
significant variation, particularly in genes associated with the mitogen-activated protein kinase (MAPK) pathway.
Notably, genes involved in response to DNA-damage stimulus were uniquely upregulated in morpheiform
BCCs. Our results indicate a relative similarity in gene expression between nodular and superficial BCC
subtypes. In contrast, morpheiform BCCs are more diverse, with gene expression patterns consistent with their
more ‘‘invasive’’ phenotype. These data may help us understand the complex behavior of BCC subtypes and
may eventually lead to new therapeutic strategies.
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INTRODUCTION
Basal-cell carcinoma (BCC) (Pinkus, 1970; Kruger et al.,
1999) is the most common neoplasm of humans (Miller,
1991a, b), which arises from the basal layer of the epidermis
or the pilosebaceous adnexa (Kruger et al., 1999). Although
BCCs are a non-metastatic malignancy, if left untreated, the
tumors can invade locally, causing significant destruction to
the surrounding soft tissues (Armstrong and Kricker, 2001).
Histopathologically, BCCs can be classified into nodular,
micronodular, superficial, infiltrative, morpheiform, and
mixed BCC forms (Sloane, 1977; Sexton et al., 1990; Rippey,
1998). Clinical and histological subtypes of BCC may exhibit
different patterns of behavior and may even have a different
etiology (Betti et al., 1995; McCormack et al., 1997;
Bastiaens et al., 1998; Scrivener et al., 2002; De Vries
et al., 2004). The distinction between these different BCC
types is important for prognosis and treatment, as more
aggressive therapy might be necessary for specific BCC
variants (Orengo et al., 1997).
Activation of the Hedgehog (Hh) pathway is required in
the pathogenesis of most BCCs (Bale and Yu, 2001;
McMahon et al., 2003). Somatic alterations of Sonic Hh
(SHH), receptor Patched (PTCH1), and SMOH have been
identified in BCCs (Gailani et al., 1996; Reifenberger et al.,
1998; Lam et al., 1999). In addition, mice ectopically
expressing the human Cubitus interruptus homolog GLI-1 in
the skin develop tumors closely resembling human BCCs
(Nilsson et al., 2000). The common effect of these genetic
alterations is constitutive activation of the Hh pathway and
transduction of the target genes. Furthermore, 56% of BCCs
also present with p53 mutations (Soehnge et al., 1997). While
the Hh pathway plays the defining role in the fate of BCC
development, the downstream consequences of its constitu-
tive activation are less well defined. How the Hh pathway
activation ultimately leads to a BCC phenotype is relatively
poorly understood.
Although the nature of different cancer phenotypes is
diverse, it has been shown that there are relatively few
signaling pathways common to cancer formation (Kastan
et al., 1991; Hanahan and Weinberg, 2000; Futreal et al.,
2004). Modulation of these pathways through differential
gene expression elicits the hallmarks of cancer: apoptosis
evasion, self-sufficiency in growth signals, angiogenesis,
tissue invasion, and unlimited replication (Hanahan and
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Weinberg, 2000). Although contribution of all these hall-
marks to BCC development may be debatable given that
BCCs are typically non-metastatic, it is likely that at least
some gene pathways defined in other forms of cancer will
also play a key role in BCC tumorigenesis. Examining the
changes in biologically meaningful sets of genes within
these pathways may provide a better understanding of the
biological process underlying BCC development (Wong
et al., 2003).
Recent advances in genome technologies have provided
an excellent opportunity to determine the complete biologi-
cal characteristics of neoplastic tissues, potentially resulting
in improved diagnosis and development of superior thera-
peutic strategies. DNA microarray analysis can accomplish
this objective and establish sophisticated algorithms (Bertucci
et al., 2001; Ramaswamy and Golub, 2002). Using DNA
microarrays has also provided important insights into the
molecular heterogeneity of cancers and identification of
individual genes whose expression is associated with prog-
nosis (Beer et al., 2002; Jenssen et al., 2002; Pomeroy et al.,
2002; Rosenwald et al., 2002; Shipp et al., 2002; van’t Veer
et al., 2002). Two microarray analyses of BCC have been
published. The first study involved a limited cDNA micro-
array representing 1,718 genes and consequently provided a
restricted data set for analysis (Howell et al., 2005). The
second, recent study comprehensively evaluated 54,675
gene transcripts in 20 BCC samples versus five normal skin
samples (O’Driscoll et al., 2006). However, no published
microarray studies have evaluated different subtypes of BCC
and compared their respective gene expression profiles.
We proposed that the phenotypic diversity of BCCs might
be accompanied by a corresponding diversity in gene
expression patterns, which could be captured using cDNA
microarrays. By evaluating histologically confirmed super-
ficial, nodular, and morpheiform BCCs, we anticipated the
identification of genes and signaling pathways common to all
three BCC subtypes, which may define the nature of BCC
neoplasias. In addition, we anticipated defining gene expres-
sion specific for each BCC subtype and possibly elucidating
new avenues for future therapeutic treatment development.
RESULTS
Comparison of sample expression profiles by hierarchical
clustering
A hierarchical clustering of unfiltered data from each tissue
sample was conducted (Figure 1). Most of the conditions
(normal epithelium, superficial BCCs, nodular BCCs,
morpheiform BCCs) segregated well in this method. Normal
skin epithelium was clearly separated from all BCC subtypes
with distinct gene expression profiles, but with close
similarity within the group. Superficial and nodular tissue
samples also yielded relatively distinctive expression profiles.
However, morpheiform BCC expression profiles tended to
be distributed among the superficial and nodular tumor
types, and were less readily identified by computer analysis
as a distinct entity. This is most likely due to a relative
heterogeneity of this kind of BCC subtype. Overall, the data
support the clinical and histological BCC subtype distinction
at the molecular level.
Gene expression common to all BCC subtypes versus skin
epithelium
Gene expression across all BCC subtypes together (all 23
BCC samples as a single group), as compared with normal
Normal Nodular SuperficialMorpheiform
Figure 1. Hierarchical clustering of samples. Unfiltered raw microarray data from each sample of normal skin epithelium (circles), superficial BCC (stars),
nodular BCC (triangles), and morpheiform BCC (squares) were clustered by Pearson correlation and distances between clusters were calculated by average
linkage. Normal epithelium samples were distinct from BCCs and closely similar in expression profiles. Of BCC subtypes, morpheiform BCCs exhibited
the greatest heterogeneity in gene expression.
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skin epithelium, was evaluated by the significance analysis of
microarray (SAM) method with a cut-off q-value of 36.84%
equating to a 95% confidence level. The results indicated that
889 genes were significantly differentially expressed in BCCs.
Of these, 88 were upregulated and 801 downregulated as
compared with normal skin epithelium. Table S2a and b
display the top 25 most differentially expressed probe sets in
all three BCC subtypes combined, compared with normal
skin epithelium.
Differential gene expression in BCC subtypes
The most differentially expressed genes compared with
normal skin epithelium were then identified within each of
the three different groups of BCC subtypes: superficial,
nodular, and morpheiform. After analysis of data by the
SAM method, we identified 4,037 probe sets (set 1) as being
differentially expressed between nodular BCCs and normal
skin epithelium, 1,914 probe sets (set 2) between morphei-
form BCCs and normal skin epithelium, and 397 probe sets
(set 3) between superficial BCCs and normal skin epithelium.
Table S3a–f display the 20 most differentially expressed probe
sets ordered by decreasing evidence for differential gene
expression between each BCC subtype, compared with
normal skin epithelium.
Differential gene expression common to all BCC subtypes
versus normal skin epithelium
Based on comparison between gene sets 1, 2, and 3, we
obtained a common set of genes (set 4) expressed in all three
BCC subtypes. In all, 164 genes were identified by the SAM
method in all three BCC subtypes, as compared with normal
skin epithelium. The top 20 common genes identified with
significant differential expression in all three BCC subtypes,
compared with normal skin epithelium, are listed (Table S4).
Unique and differential BCC subtype gene expression analyses
Cross-comparison of gene lists (analysis of differentially and
similarly expressed gene sets derived from sets 1, 2, and 3;
see Materials and Methods) for each BCC subtype was
conducted to identify those genes with statistically significant
expression unique to only one of the three BCC subtypes. We
identified 11, 343, and 94 genes with a statistically significant
fold change in expression unique to superficial, nodular, or
morpheiform BCCs, respectively (Table S5a–f). In principle,
these tables of differential gene expression may represent
signal transduction pathways and mechanisms which might
determine the specific phenotype of each respective BCC
subtype. In addition, we conducted pairwise comparisons
between conditions using the SAM method to define
differential gene expression between BCC subtypes, without
relation to gene expression in normal skin epithelium, and
between all BCCs and skin epithelium. For each comparison,
we report the 25 up- and downregulated genes that had the
lowest expected false discovery rate (Table S6a–h).
Ontological analysis of BCC subtypes
To analyze whether genes with specific functions were
over- or under-expressed in the three subtypes of BCCs, we
analyzed each subtype’s composition of differentially
expressed genes separately (gene sets 1, 2, and 3) with
respect to their gene ontology (GO annotation), as given in
the DAVID annotation system. Of significant interest, some
GO categories were uniquely represented in respective BCC
subtypes (Table S7). Only one GO class, ‘‘external stimuli
function’’, was defined as being uniquely expressed in
superficial BCC subtypes but not nodular or morpheiform
BCCs. Gene enrichment in the categories of ‘‘regulation of
cell growth’’ and ‘‘negative regulation of enzyme activity’’
were characterized in nodular BCCs, among others. In
contrast, two functional GO categories, ‘‘response to DNA
damage stimulus’’ and ‘‘ectoderm development’’, were
uniquely identified with statistically significant expression
in morpheiform BCCs, but not superficial or nodular BCCs.
Tumor progression pathway analysis
Recent publications have promoted the value of examining
gene expression data in terms of signal transduction networks
represented rather than individual genes expressed (Wong
and Chang, 2005). Using gene sets 1, 2 and 3, classified
respectively in terms of their GO annotated roles, we defined
the statistical significance of pathways and categories of
genes represented using Fisher’s gene-enrichment calculation
and subsequently further defined more specific descriptions
(GO level 5). By subdividing the list into distinct sets of genes
that were pathway-specific, we found that the most strongly
represented bias, in terms of the number of genes differen-
tially expressed across all three BCC subtypes, was toward
apoptosis and its regulation (Table S8).
Focusing only on genes involved in established pathways
of tumorigenesis (the Hh, Wnt, transforming growth factor-b,
apoptosis, calcium ion channel, mitogen-activated protein
kinase (MAPK), or cell-cycle-signaling pathways), we identi-
fied 93 genes (using a 36.84% SAM q-value cut-off) that were
differentially expressed between all BCCs and normal skin,
and were also involved in one or more of the seven identified
pathways. Seventeen genes were involved in the Hh-
signaling pathway, 27 in the Wnt-signaling pathway, 22 in
the transforming growth factor-b-signaling pathway, 89 in
apoptosis, 18 in calcium channel signaling, 22 in MAPK, and
21 in cell cycling. Upon comparing every two BCC subtypes
with each other, we found that the predominant signal
transduction pathway with the greatest difference in the
number of differentially expressed, pathway-associated genes
was the MAPK pathway (data not shown). The MAPK
pathway is of significant interest in understanding BCC
subtypes, given its interaction with many cellular systems
and other signal transduction pathways, including Hh and
Wnt pathways.
Validation of the expression of selected genes
With the microarray analysis of the three BCC subtypes
complete, we selected genes with known functional signi-
ficance, primarily within the apoptosis and MAPK pathway
categories, for evaluation by quantitative PCR (qPCR).
Selected genes, particularly those associated with the
Hh- and cell-cycle-signaling pathways, were also evaluated,
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even though they did reach statistical significance in the SAM
analysis. Although the fold change in expression defined by
qPCR was different from that observed by microarray, the
trends, whether for increased or decreased gene expression,
were mostly consistent for each respective gene examined
and the majority of evaluated genes were expressed with
statistically significant differences in expression (Table S9).
The majority of genes presented with a modest fold change in
expression in superficial BCCs, but with greater differential
expression in nodular and morpheiform BCCs. A similar trend
pattern emerged for many genes evaluated by qPCR.
However, a few genes identified with the greatest fold
change in gene expression in nodular and superficial BCC
subtypes by microarray were confirmed by qPCR as most
highly expressed in the respective BCC subtypes (Figure 2).
Variability in mRNA expression within BCC subgroups was
apparent, but results were statistically significant between
groups. Such differences in gene expression might potentially
be utilized as molecular identifiers of specific BCC subtypes.
As a validation of product expression signaled by micro-
array and qPCR results, we conducted immunohistology to
define cyclooxygenase-2 (COX2) expression in pathology
specimens from the superficial, nodular, and morpheiform
BCCs. The results were consistent with the pattern of COX2
mRNA expression observed. Low, or almost no, COX2 was
consistently seen in superficial BCCs (Figure 3a). Expression in
nodular BCCs varied with location and specimen, but overall
suggested a moderate presence (Figure 3b), whereas COX2
was readily identified in the invasive threads of morpheiform
BCCs (Figure 3c).
DISCUSSION
Comparison to previously published microarray analyses
Thus far, no published studies have compared the gene
expression profiles of different, histologically confirmed BCC
subtypes using microarrays. Only two microarray-based
studies have been published, which compare BCC tissues
with normal skin epithelium (Howell et al., 2005; O’Driscoll
et al., 2006). Comparison of our data with already published
datasets identify a number of confirmatory observations when
considering that our gene expression sets observed are
common to all three BCC subtypes (Table S2a and b).
Notably, some genes are well represented both in previous
studies and in our current evaluation, which include the
following: collagen, type IV, a1 (COL4A1), collagen, type V,
a2 (COL5A2), collagen, type VI, a1 (COL6A1), syndecan 2
(SDC2), and tumor-associated calcium signal transducer 1
(TACSTD1), among others. However, despite the notable
confirmation of a few highly expressed genes between the
two studies (such as chromogranin A (CHGA)), comparison of
our datasets with those of O’Driscoll and co-workers suggests
a greater number of differences between the gene expression
profiles. How much of this difference is due to the differences
in the cDNA microarray platforms and statistical analysis
approaches used is not known. Most likely, the differences in
the tissue samples and the nature of BCC subtypes utilized in
each study have determined the distinctions in results.
Gene expression and function across BCC subtypes
To analyze whether genes with specific functions were over-
or under-expressed in the three subtypes of BCCs, we
analyzed each subtype’s composition of the filtered and
tested genes with respect to their GO annotation. Several GO
classifications were well represented in all three BCC
subtypes, including cell motility, cellular morphogenesis,
negative regulation of cellular process, positive regulation of
cellular process, and cellular metabolism. These classifica-
tions have all been suggested to play significant roles in
carcinogenesis in different tumors (Kunz-Schughart et al.,
2000; Mazars et al., 2000; Jeon et al., 2004; Liou et al., 2004;
Zhivotovsky and Orrenius, 2006). However, within a
category, each BCC subtype had different numbers of genes
and different degrees of fold change in expression. By both
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Figure 2. Characterization of gene expression patterns across BCC subtypes.
COX2, AIF1, and TNRSF10D were selected as examples of genes defined
by microarray as having increased fold change expression in the
morpheiform, nodular, or superficial BCC subtypes, respectively. Plotting of
qPCR validation results confirmed that COX2 was statistically significantly
expressed in morpheiform BCCs, whereas AIF1 was most highly expressed in
nodular BCCs and TNRFSF10D was highly expressed in superficial BCCs
(*¼Po0.05). AIF1, apoptosis-inducing factor 1.
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Figure 3. COX2 expression in BCC subtypes. Immunohistochemistry
consistently identified almost no expression of COX2 in superficial BCCs (a),
and moderate expression in nodular BCCs (b), whereas tongues of neoplastic
basaloid cells in morpheiform BCCs in relatively collagenized stroma
exhibited consistent COX2 expression (c). Bars¼50 mm.
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microarray technique and qPCR, most genes evaluated were
found with moderate increased expression in superficial
BCCs, but with a much greater level of differential expression
in nodular and morpheiform BCCs. Examples of this trend
included MMP1, DPP4, and ATP2B1 (Table S9). While genes
may be commonly expressed in all three BCC subtypes, their
different levels of expression will be important for deter-
mining differences in BCC subtype morphology.
The gene function classes enriched in superficial BCC
subtypes showed a significant association with ‘‘external
stimuli function’’ and possibly ‘‘positive regulation of enzyme
activity’’ (Table S7). In nodular BCCs, gene enrichment in the
categories ‘‘regulation of cell growth’’, ‘‘cell growth’’, and
‘‘chromosome segregation’’ were identified, among others.
The combination of these functional categories might be
relevant for development of the nodular phenotype. Two
functional GO categories, ‘‘ectoderm development’’ and
‘‘response to DNA damage stimulus’’, were uniquely
identified with statistically significant expression exclusively
in morpheiform BCCs. Genes from these categories such as
inducible enzyme COX2 might be a focus of interest. Studies
have suggested that overexpression of COX2 might induce
the expression of vascular endothelial growth factor, increase
angiogenesis, and enhance tumor growth, metastasis, and
tumor spread (Tong et al., 2000; Uefuji et al., 2000;
Ferrandina et al., 2002; Li et al., 2006). We found that
COX2 was somewhat expressed in nodular BCCs, but much
more so in morpheiform BCCs, by qPCR. We were also able
to confirm a difference in the presence of COX2 product in
the three BCC subtypes, by immunohistology. The expression
of genes associated with angiogensis in morpheiform BCCs
may reflect the more aggressive/invasive activity of this BCC
subtype, and could be markers for diagnosis and perhaps a
target for future tailor-made therapeutic strategies.
Hh and Wnt signal transduction pathways
The underlying signal transduction pathways known to be
functionally important in BCC growth, the Hh and Wnt signal
transduction pathways (McMahon, 2000), were detected in all
three subtypes of BCCs. With the notable exception of Gli2,
the stringency of the microarray analysis resulted in a lack of
statistical significance in many Hh pathway-associated genes,
although greater than 1.5-fold mean changes in expression
were apparent. However, several Hh pathway-associated
genes were identified with significant differential expression
in all BCC subtypes. GLI transcription regulators AKT1,
IGFBP4, IGFBP2, and PRKACA were upregulated in all BCCs
(Epstein et al., 1996; Hammerschmidt et al., 1996; Riobo
et al., 2006; Sheng et al., 2006). Subsequent evaluation by the
more sensitive qPCR technique confirmed upregulation of
PTCH1,GLI1,GLI2, and PRKACA in BCC subtypes (Table S9).
Other Hh pathway-associated genes identified in microarray
results and re-evaluated by qPCR included SFRP2 and
BMPR2, both of which exhibited upregulation in the BCCs,
with fold change greater in nodular and morpheiform types
(Table S9).
Expression of Wnt family members, including CCND2,
CAMK2G, CSNK2A2, and especially frizzled receptors for
Wnt proteins, FZD7, FZD8, and FZD2, was deregulated in
BCCs. These genes are known to play a role in several types
of cancers (Janssens et al., 2004; Milovanovic et al., 2004;
Vincan et al., 2005). By microarray analysis, levels of
differential expression for most Wnt pathway-associated
genes were found to be similar across the three BCC
subtypes. However, by qPCR, WNT5A and FZD2 were
observed with the greatest fold increase in nodular BCCs and
the least in superficial BCCs (Table S9). Overall, these
changes in expression are consistent with the involvement of
the canonical Wnt-signaling pathway in BCCs. In addition,
we found evidence consistent with the activation of the non-
canonical Wnt/Ca2þ pathway (Miller et al., 1999; Kuhl et al.,
2000; Ishitani et al., 2003).
Apoptosis pathway
There are two major apoptotic pathways initiated by either
mitochondria (‘‘intrinsic’’ pathway) or death receptors
(‘‘extrinsic’’ pathway) (Engels et al., 2000; Sorlie et al.,
2001; Liu et al., 2004). Our microarray data showed that
genes in both pathways were differentially expressed,
although statistical significance was not always achieved
using SAM analysis. For example, differential fold change
expression of decoy TRAIL receptor 4 (TNFRSF10D), which
protects against TRAIL-mediated apoptosis, failed to reach
statistical significance in SAM analysis. However, by qPCR
there was statistically significant upregulation, most notably
with highest expression in superficial BCCs. TNFRSF6B,
coding for DcR3, which binds to FasL inhibiting its
proapoptotic action (Tsuji et al., 2003), was upregulated
much more so in nodular and morpheiform BCCs than in
superficial BCCs (Table S9). Many genes have been
implicated in the process of mitochondria-mediated apopto-
sis, including the Bcl family, the inactivation of which might
contribute to tumor progression (Huang, 2000; Antonsson,
2001). Consistent with Bcl family-associated mechanism
activity, we found reduced levels of BCL2L2, BCL3, BCL6,
and BCL7B. In contrast, BCL2L11, BCL7C, BCL10, and
BCL11B were upregluated along with somewhat increased
levels of upstream proto-oncogene AKT1. Overall, the results
suggested that BCC cells may exhibit mechanisms to evade
apoptosis, particularly in morpheiform BCCs, allowing cell
survival and increased proliferation (Erb et al., 2005).
MAPK-signaling pathway
MAPKs are evolutionary conserved enzymes connecting cell-
surface receptors to critical regulatory targets within cells
(Strniskova et al., 2002). Mammals express at least four
distinctly regulated MAPK components, extracellular signal-
related kinases, Jun amino-terminal kinases (JNK1/2/3), p38
proteins (p38a/b/g/d) and extracellular signal-related kinase-5
(Chang and Karin, 2001). Of the members of the MAPK-
signaling pathway, Ras and Raf have been identified as proto-
oncogenes, where gain-of-function (activating) mutations
have been identified in many cancers (Hussein, 2005). We
found increases in the expression of many Ras superfamily
members in all three BCC subtypes, such as RAB31, which
has also been identified in breast cancer (Abba et al., 2005),
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and RAB3A, which is enhanced in harderian tumors in mice
(Vadlamudi et al., 2000). In contrast, tumor suppressor genes
such as DUSP2 and RASSF1 (Akino et al., 2005) were
reduced in expression. These results and others suggested that
the RAS-MAPK-signaling pathway is significantly activated
and may play a key role in BCC carcinogenesis. However, we
were unable to obtain statistically significant results for
RAB3A and DUSP2 by qPCR. Nevertheless, given that
receptors associated with Ras activation seem to be effective
targets for treating breast cancer (Slamon et al., 2001), this
family may be worthy of further investigation.
Conclusions
This study identifies genome-wide gene expression profiles of
superficial, nodular, and morpheiform BCC subtypes. Our
results indicated that several of the signaling pathways
identified in other forms of cancer are well represented in
BCCs. Some specific categories of genes were identified in
specific BCC subtypes and these categories/genes may
determine the particular clinical and histological BCC
phenotypes. Where genes were commonly expressed in all
three BCC subtypes, they typically presented with greatest
fold change in expression in morpheiform BCCs, suggesting
that morpheiform BCCs are more ‘‘aggressive’’ compared
with superficial and nodular BCCs. Many of the genes
defined may regulate pathways essential for BCC formation in
human skin and could eventually represent potential
therapeutic targets. Further exploration of the relevant
mechanisms of pathogenesis will improve our understanding
of the molecular basis of BCC.
MATERIALS AND METHODS
BCC tissues and clinical information
Human BCCs and normal skin tissues were obtained from 31
patients at the Department of Dermatology and Skin Science,
University of British Columbia. Investigations were performed
according to the Declaration of Helsinki Principles after approval
by the University Clinical Research Ethics Committee. Specific
patient consent was not required because Canadian law considers
human tissue excised during surgery as discarded material. For
microarray analysis, superficial (8), nodular (8), morpheiform (7),
and microdissected normal skin epithelium (8) tissue samples were
collected. All of the samples were taken from the facial area. Of
these 31 samples, 18 were derived from males (45–75 years of age
with a mean±SD of 57.4±7.90 years) and 13 from females (43–84
years of age with a mean±SD of 59.4±11.73 years). Samples were
collected in the operation theater during Moh’s surgical excision and
were immediately stored in an RNA stabilization reagent (Qiagen
Inc., Mississauga, ON, Canada). Only tissues from patients who had
not been treated with preoperative chemotherapy or other thera-
peutic approaches were selected. BCC morphological subtypes were
described and classified during surgery, and clinical diagnoses
were subsequently confirmed by formalin-fixed, paraffin-embedded
histological assessment of the tumors.
RNA isolation
Total RNA was isolated with an RNeasy Fibrous Tissue Midi kit
(Qiagen) according to the manufacturer’s protocols. The quantity
and quality of the RNA were measured using an Agilent 2100
bioanalyzer and the RNA 6000 NANO kit (Agilent Technologies,
Palo Alto, CA).
Microarray production
Human Operon v.2.1 (21K) glass arrays were designed (based on
human 70-mer from Operon Biotechnologies Inc., Huntsville, AL) by
the Microarray Facility of the Prostate Centre at Vancouver General
Hospital, Vancouver, Canada (Lyons, 2003; Nelson et al., 2003).
RNAs were amplified using the SenseAmp Plus kit (Genisphere Inc.,
Hatfield, PA). The calculated A 260/280 ratio was used to determine
the appropriate amount of sense RNA for labeling. Total RNA from
test samples and universal human reference RNA (Stratagene, Cedar
Creek, TX) were differentially labeled with Cy5 and Cy3, respec-
tively, using the 3DNA array detection 350 kit (Genisphere Inc.), and
co-hybridized to cDNA microarrays. Following overnight hybridiza-
tion and washing, arrays were imaged using a ScanArray Express
scanner (PerkinElmer, Boston, MA).
Data processing and analysis
Arrays were scanned at excitation wavelengths of 532 and 635 nm to
detect the Cy3 and Cy5 dyes, respectively. Image analysis and
quantification were conducted with commercial software (Imagene
6.0 software; Biodiscovery Inc., El Segundo, CA). After grid
assignment, the adjusted intensity for each gene was calculated by
subtracting the background median from the signal median. This
value was used as input for the Genespring 7.2 program (Silicon
Genetics, Redwood City, CA), which allows multiple filter compar-
isons using data from different experiments to perform normali-
zation, generation of restriction lists, and the functional classification
of the differentially expressed genes. Raw data were used in ‘‘per
chip and per spot normalization’’, which was intensity-dependent
(non-linear or LOWESS normalization) (Yang et al., 2002). The
expression of each gene is reported as the ratio of the value obtained
after each condition relative to control conditions after normali-
zation of the data. Data were subsequently filtered using the raw
signal strength value. Measurements with higher signal strength
value are relatively more precise than measurements with lower
control strength. Consequently, genes with expression that did not
reach the minimum signal value (100 arbitrary units) were discarded.
We generated a condition tree using hierarchical clustering of
unfiltered data from each sample, based on the similarity of their
expression data. Similarity was measured using Pearson correlation
and distances between clusters were calculated by average linkage.
All raw data from the arrays have been entered into the public Gene
Expression Omnibus (GEO) database in MIAME compliant format
(http://www.ncbi.nlm.nih.gov/geo/). The raw data sets are included
under the series record number GSE6520.
Analysis of gene expression differences between BCC subgroups
and unique to BCC subtypes
SAM was used to identify genes differentially regulated between skin
epithelium and the respective subtypes of BCCs. SAM is a statistical
technique for finding significant genes in a set of microarray
experiments (Tusher et al., 2001). It assigns a score to each gene
on the basis of change in the gene expression relative to the standard
deviation of repeated measurement. It then uses permutations of the
repeated measurements to estimate the false discovery rate. After
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filtering, three respectively statistically significant difference gene
lists (sets 1, 2, and 3, see below) between BCC subtypes and skin
epithelium were identified. To find genes common to all three
subtypes (Table S4), they had to pass a false discovery-corrected
q-value of 36.84% for every subtype compared with normal skin
individually. This ensured that the chance that a gene made it into
the list without having any relevance to any of the subtypes was
below 5% (95% confidence interval). This was calculated from the
initial 36.84% by 0.36843 (cubed)¼ 0.05. To define the degree of
similarity in gene lists derived from different subtypes of BCCs
compared with skin epithelium, the q-value for one subtype had to
be below 36.84% and above 100–36.84%¼ 63.16% in the other
subtypes (Table S5a–f). For comparison of gene expression in BCC
subtypes, we also used the SAM technique to identify the gene lists
(Table S6).
GO and pathway analysis
The functional classification of genes is based on the GO database
and allows the identification of ‘‘enriched’’ or ‘‘depleted’’ gene
function categories in assigned biological processes, molecular
functions, and cellular components (Harris et al., 2004). We
analyzed the GO annotation for the genes that were significantly
different between the BCCs and normal skin, using a web-based
annotation tool (DAVID version 2 software, http://david.abcc.
ncifcrf.gov/) for identified ‘‘enriched’’ function annotations. This
program identifies genes belonging to different GO categories and
also calculates the statistical significance of non-random representa-
tion (that is, overlapping P-values) with Fisher’s exact test.
A P-valuep0.01 indicates that the user gene list is specifically
associated (enriched) in this category, as compared with random
chance. Potential false positives in our gene list, which can result
from technical insufficiencies and low case numbers, become
randomly distributed among the GO classes and thus any significant
association identified should result from the distribution patterns of
the true positives. For 25–40% of the genes defined, no GO
annotation was given and their function is unknown. The numbers of
genes identified in major categories were normalized by the number
of genes annotated in each list and were expressed as percentages
(Dennis et al., 2003). To assess which signaling pathways were
affected during gene regulation, the genes were classified and
grouped into different pathways using Genespring software. Pathway
information was imported from the Kyoto encyclopedia of Genes
and Genomes.
qPCR analysis for gene expression
To verify the alterations of gene expression at the mRNA level
identified by microarray, we chose representative genes with varying
expression profiles for qPCR. The sequences of the complete genome
were obtained from GenBank. A pair of oligonucleotide primers was
designed for each sequence using Primer 3 software (http://frodo.
wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), using the following
criteria: 50–65 1C melting temperature, 40–60% GþC content,
18–25-bp primer length, and 75–250-bp amplicon size. Primer
sequences are listed in Table S1.
Two micrograms of total RNA from each sample were subjected
to reverse transcription using the Superscript first-strand cDNA
synthesis kit (Invitrogen Life Technologies, Carlsbad, CA) according
to the manufacturer’s protocol. qPCR reactions were then conducted
using a total of 25 ml of reaction mixture (2ml of cDNA, 12.5 ml of
2 SYBR Green PCR Master Mix (Qiagen), 1.5 ml of each 5mmol l1
forward and reverse primers (Invitrogen), and 7.5 ml of H2O) in an
Opticon DNA Engine (MJ Research, Waltham, MA). The PCR
program was initiated for 10minutes at 95 1C before 40 thermal
cycles, each of 15 seconds at 94 1C, 30 seconds at 60 1C, and
30 seconds at 72 1C. Preliminary research comparing housekeeping
genes b-actin, glyceraldehyde-3-phosphate dehydrogenase, and
QuantumRNA Universal 18S internal standard primers (Ambion
Inc., Austin, TX) in collected tissues by reverse transcriptase-PCR,
identified 18S as most consistently expressed in skin (data not
shown). 18S was subsequently used for all analyses described.
Reverse transcriptase-PCR data were analyzed according to the
comparative Ct method, and were normalized against 18S expres-
sion in each sample. Melting curves for each PCR reaction were
generated to ensure the purity of the amplification product.
Immunohistology
Protein expression COX2 was explored in BCC subtypes by
immunohistochemistry. Briefly, paraffin-embedded tissue sections
were processed, rehydrated, and antigen-unmasked by immersion in
10mM sodium citrate buffer at 90 1C. After blocking with normal
rabbit serum and alkaline phosphatase ablation with levamisole
(Vector Laboratories, Burlingame, CA), rabbit anti-human COX2
(Cell Signaling Technology, Danvers, MA), dextran polymer-
conjugated anti-rabbit, alkaline phosphatase amplification polymer,
and substrate (all from Vector Laboratories) were applied in
sequence. Sections were counterstained with Harris’ hematoxylin
and mounted in Permount (Fisher Scientific, Ottawa, ON, Canada).
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SUPPLEMENTARY MATERIAL
Table S1. Primer sequences for defined genes.
Table S2a. Gene transcripts with significant upregulation common to BCCs
versus normal skin epithelium.
Table S2b. Gene transcripts with significant downregulation common to BCCs
versus normal skin epithelium.
Table S3a. Gene transcripts with significant upregulation in superficial BCCs
versus normal skin epithelium.
Table S3b. Gene transcripts with significant upregulation in nodular BCCs
versus normal skin epithelium.
Table S3c. Gene transcripts with significant upregulation in morpheiform
BCCs versus normal skin epithelium.
Table S3d. Gene transcripts with significant downregulation in superficial
BCCs versus normal skin epithelium.
Table S3e. Gene transcripts with significant downregulation in nodular BCCs
versus normal skin epithelium.
Table S3f. Gene transcripts with significant downregulation in morpheiform
BCCs versus normal skin epithelium.
Table S4a. Common genes identified with significant increased expression in
all three BCC subtypes compared with normal skin epithelium.
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Table S4b. Common genes identified with significant decreased expression in
all three BCC subtypes compared with normal skin epithelium.
Table S5a. Genes with increased expression exclusively identified in
superficial BCCs.
Table S5b. Genes with increased expression exclusively identified in nodular
BCCs.
Table S5c. Genes with increased expression exclusively identified in
morpheiform BCCs.
Table S5d. Genes with decreased expression exclusively identified in
superficial BCCs.
Table S5e. Genes with decreased expression exclusively identified in nodular
BCCs.
Table S5f. Genes with decreased expression exclusively identified in
morpheiform BCCs.
Table S6a. Gene transcripts with significant upregulation in morpheiform
BCCs versus nodular BCCs.
Table S6b. Gene transcripts with significant downregulation in morpheiform
BCCs versus nodular BCCs.
Table S6c. Gene transcripts with significant upregulation in morpheiform
BCCs versus superficial BCCs.
Table S6d. Gene transcripts with significant downregulation in morpheiform
BCCs versus superficial BCCs.
Table S6e. Gene transcripts with significant upregulation in nodular BCCs
versus superficial BCCs.
Table S6f. Gene transcripts with significant downregulation in nodular BCCs
versus superficial BCCs.
Table S6g. Gene transcripts with significant upregulation in all BCCs versus
skin epithelium.
Table S6h. Gene transcripts with significant downregulation in all BCCs
versus skin epithelium.
Table S7. GO analysis of biological processes represented by differential gene
expression observed by BCC subtype.
Table S8. Gene ontology analysis of biological processes represented by
differential gene expression observed common to all BCC subtypes.
Table S9. Selected gene validation results by qPCR with corresponding
microarry results for comparison.
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